Education-only orientation — This page is part of the iMicrodosing.org evidence library. It provides research and regulatory education only. It is not clinical advice, prescribing information, a recommendation to seek or avoid any treatment, or guidance on participating in any clinical program.

What this page does and does not contain — This page examines the clinical and regulatory landscape for psilocybin-based investigational drugs. It names clinical sponsors and trial programs only to identify their public research records and regulatory milestones. It does not: recommend or endorse any treatment, drug, or program; guide readers toward or away from any investigational therapy; facilitate trial enrollment; provide recruitment or site-location information; reproduce or endorse sponsor investor language as established efficacy; apply full-dose clinical trial findings to microdosing; or link to .com commerce properties.

TL;DR

As of mid-2026, psilocybin for PTSD has a single published Phase 2 open-label safety and tolerability study involving 22 participants [1] Clinical trial Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial McGowan NM, Rucker JJ, Yehuda R, Agrawal M, Modlin NL, Simmons H, Tofil-Kaluza A, Das S, Goodwin GM (2026) doi:10.1177/02698811251362390 and an FDA-accepted IND enabling a Phase 2b/3 trial. [2] sponsor-press-release Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD Compass Pathways plc (2026) Link → No randomized Phase 3 data exist for this indication. The PTSD evidence base is substantially less developed than the treatment-resistant depression evidence base. Findings from the TRD clinical trials do not establish efficacy for PTSD.

Where psilocybin PTSD evidence stands

The PTSD evidence landscape for psilocybin is at an early stage relative to the TRD program. The most advanced published data comes from a nonrandomized open-label Phase 2 study conducted by Compass Pathways, evaluating the safety and tolerability of a single 25 mg COMP360 dose in 22 participants with PTSD. Results were published in the Journal of Psychopharmacology in 2026. [1] Clinical trial Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial McGowan NM, Rucker JJ, Yehuda R, Agrawal M, Modlin NL, Simmons H, Tofil-Kaluza A, Das S, Goodwin GM (2026) doi:10.1177/02698811251362390 The study’s primary objective was safety, not efficacy. Open-label data without a control group do not establish that the treatment caused any observed improvement — participants knew what they were receiving, and improvement may reflect factors other than the drug’s pharmacological action.

The FDA accepted an Investigational New Drug application for COMP360 in PTSD in early 2026, enabling the initiation of a Phase 2b/3 randomized controlled trial. [2] sponsor-press-release Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD Compass Pathways plc (2026) Link → IND acceptance means the FDA has reviewed the proposed protocol and determined it is safe to proceed — not that efficacy has been established or that approval is expected.

Psilocybin evidence depth: TRD vs PTSD as of mid-2026
Evidence typeTRD (COMP360)PTSD (COMP360)
Phase 2 peer-reviewed RCTYes (COMP001, NEJM 2022) [3] Clinical trial Single-dose psilocybin for a treatment-resistant episode of major depression Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, et al. (2022) doi:10.1056/NEJMoa2206443 No
Phase 3 randomized controlled trialsTwo (COMP005, COMP006 — top-line only)None completed
IND for Phase 2b/3Not applicable (Phase 3 complete)Accepted January 2026
NDA / approval pathwayRolling NDA underwayEarly Phase 2b/3 stage
Breakthrough Therapy designationYes (TRD)Not announced as of mid-2026

Why TRD results do not transfer to PTSD

PTSD and treatment-resistant depression are different diagnoses with different symptom profiles, different neurobiological frameworks, and different clinical populations. A drug’s efficacy in one condition does not predict efficacy in another, even when the drug mechanism may engage overlapping brain systems.

Regulatory agencies evaluate efficacy for each indication separately because the clinical questions — the specific outcomes to measure, the patient populations to study, and the comparison conditions to use — differ by indication. A psilocybin program approved for treatment-resistant depression would not automatically be an approved treatment for PTSD. A separate regulatory application based on PTSD-specific Phase 3 evidence would be required.

The FDA’s guidance on psychedelic drug investigations specifically addresses the need for indication-specific evidence and controlled trial designs. [4] primary-regulatory Psychedelic Drugs: Considerations for Clinical Investigations U.S. Food and Drug Administration (2023) Link →

The MDMA context

PTSD has been the primary indication pursued by MDMA-assisted therapy programs. The Lykos Therapeutics NDA for MDMA-assisted therapy for PTSD was rejected by the FDA in August 2024, citing concerns about trial methodology, data integrity, and functional unblinding. That rejection was on specific grounds related to that application and does not determine outcomes for psilocybin or other PTSD programs. It does illustrate that even a drug that completes Phase 3 trials does not automatically receive approval.

Psilocybin for PTSD is years behind the MDMA program in stage of development. Comparing the two requires understanding that they are different molecules, different protocols, and different evidence packages.

Distinguishing PTSD and microdosing research

The COMP360 PTSD study used a single 25 mg dose under supervised clinical conditions — a full psychoactive dose, not a microdose. Reports of individuals using microdosing practices for PTSD-related symptoms exist in the observational literature, but that evidence is categorically different from a controlled clinical trial. Observational reports of self-reported improvement in uncontrolled settings cannot establish that psilocybin caused the improvement or that it is safe and effective for PTSD. See the Clinical Pipeline overview for how to hold these distinctions. See How to Read Press Releases for a framework on evidence evaluation.

Key concepts
Open-label Phase 2 safety study
A study without a control group, in which both researchers and participants know the treatment. It is designed to assess tolerability and safety signals, not to establish efficacy. Results cannot be used to attribute clinical improvement to the drug alone.
IND acceptance
The FDA’s determination that a proposed clinical trial protocol may proceed. It is a safety and protocol-adequacy determination, not an efficacy endorsement.
Indication-specific evidence
The regulatory principle that efficacy in one diagnosed condition does not establish efficacy in another. Separate clinical programs and applications are required for each indication a drug seeks approval in.
PTSD as a distinct regulatory target
PTSD has defined diagnostic criteria and specific validated outcome measures used in clinical trials. Evidence requirements for a PTSD indication are assessed independently of other psychiatric indications.
Is there any clinical evidence for psilocybin in PTSD?
As of mid-2026, evidence for psilocybin in PTSD consists primarily of a published open-label Phase 2 safety and tolerability study involving 22 participants, with no randomized Phase 3 trial data available. An IND application for a PTSD program was accepted by the FDA in early 2026, allowing a clinical trial to proceed. The PTSD evidence base is substantially less developed than the TRD evidence base.
What is an open-label study, and how does it differ from a Phase 3 trial?
An open-label study is one in which both the researchers and participants know what treatment is being given. It is used primarily to assess safety and tolerability. Because there is no blinded control group, it cannot establish efficacy with the same rigor as a randomized, double-blind, placebo-controlled trial. A Phase 3 trial uses the controlled design required to support a regulatory application.
Does COMP360 hold Breakthrough Therapy designation for PTSD?
No. As of the lastReviewedDate, COMP360 held Breakthrough Therapy designation for treatment-resistant depression. The PTSD program was at the IND-accepted stage, enabling Phase 2b/3 clinical trial initiation. Breakthrough Therapy designation for the PTSD indication had not been announced.
Why is PTSD evidence for psilocybin at a different stage than MDMA evidence?
MDMA-assisted therapy for PTSD completed two Phase 3 trials before the FDA rejected the NDA from Lykos Therapeutics in 2024 due to concerns about trial methodology, data integrity, and functional unblinding. Psilocybin for PTSD is in early Phase 2 investigation, years behind the MDMA program’s stage of development. The rejection of the MDMA NDA was on specific grounds related to that application and does not determine outcomes for psilocybin.
Do the COMP360 TRD results mean psilocybin would work for PTSD?
No. PTSD and treatment-resistant depression have different diagnostic criteria, different symptom profiles, different neurobiological theories, and different regulatory evidence requirements. A positive TRD trial result does not establish efficacy in PTSD. Separate Phase 3 evidence specific to PTSD would be required to support any regulatory application for that indication.